Haut recently served as the chief business officer of AskBio, a clinical-stage developer of gene therapies and technologies. During his tenure at the company, Haut played a key role in pharmaceutical giant Bayer AG’s $4 billion acquisition of AskBio.
Haut earned his PhD in molecular biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.
READ: Antibe Therapeutics plans to unify the intellectual property ownership of its drugs and platform
“I am delighted to welcome another superstar to our Partnering Advisory Team,” said Dan Legault, Antibe’s CEO in a statement. “Don’s broad background and tremendous recent success will add new depth to our business development capability as our partnering activities accelerate in 2021.”
Haut told shareholders that Antibe’s platform “promises a major advance” in the treatment of pain and inflammation-based disease.
“This area is overdue for disruption and represents a massive commercial opportunity,” Haut said. “I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.”
Toronto-based Antibe is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief.
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas